GHK-Cu / BPC-157

GHK-Cu / BPC-157 is a vendor name for two peptides sold in one vial, usually a 5:1 ratio of GHK-Cu to BPC-157, the same pair that makes up two thirds of GLOW without the TB-500. No study, animal or human, has tested the two given together. BPC-157’s published sequence happens to contain none of the amino acids copper oxidation chemistry usually targets, which is a genuine point in this pairing’s favor, but it is not a stability study, and nobody has actually tested whether copper transfers between the two peptides in solution. Neither component is an approved drug.

Ask about GHK-Cu + BPC-157 combination

Research snapshot

Peptide categoryTwo-component peptide blend (copper-binding tripeptide + gastric-derived repair peptide)
Primary research interestSkin and connective-tissue repair (component-level reputations; combination itself untested)
Highest available evidenceTier 5 for the combination, no study, animal or human, has tested the two given together
Human research availableNo trial of the combination; each component has its own separate, limited human evidence base
Development statusNot a formulated drug product; a vendor-mixed blend
Regulatory statusNeither component is an approved drug

Technical identity (composition)

Primary nameGHK-Cu / BPC-157 blend (vendor name)
CompositionGHK-Cu (copper-binding tripeptide) + BPC-157 (synthetic gastric-juice-derived peptide fragment)
Share of vial by massMost commonly described split: GHK-Cu 50 mg to BPC-157 10 mg, a 5:1 ratio (about 83% / 17% by mass)
Peptide sequenceNot applicable, a multi-component mixture; see individual GHK-Cu and BPC-157 pages for each molecule’s sequence
Molecular formulaNot applicable, a multi-component mixture, not a single molecular entity
CAS Registry NumberNot applicable, no CAS number is assigned to the combination itself
Chemical modificationsNot applicable at the combination level; see individual component pages
Developer or originatorNot applicable, a vendor-mixed blend, not a developed drug product
Development statusNot in formal development; no INN, no approved status

What it is

GHK-Cu / BPC-157 is a vendor name for two peptides in one vial: GHK-Cu, a copper-binding tripeptide, and BPC-157, a synthetic fragment derived from a protein found in gastric juice. It is the same pair that makes up two thirds of GLOW, sold here without the TB-500. It has no INN, no CAS number of its own and no approved indication anywhere.

The name is easy to confuse with its relatives. Wolverine is BPC-157 and TB-500, no GHK-Cu at all. GLOW is this pair plus TB-500. KLOW is GLOW plus KPV. A product sold under any of the four names may in practice be any of the four compositions, and the name alone does not tell a buyer which.

What is actually in the vial

The most commonly described split is GHK-Cu 50 mg to BPC-157 10 mg, a 5:1 ratio by mass, usually reconstituted in 3 mL of bacteriostatic water. That GHK-Cu figure matches the GHK-Cu content of the GLOW and KLOW vials already on this site, which suggests 50 mg is a round-number convention for the GHK-Cu component across several blend products rather than something specific to the two-peptide version. As with every other blend on this site, no independent, dated survey of multiple vendor listings for this specific two-peptide product was carried out for this entry, and no dose-ranging study has ever compared this ratio against any other.

The copper question

Putting a copper-binding peptide in the same vial as another peptide raises an obvious question: does the copper do anything to the other molecule? GHK-Cu holds its copper ion tightly enough to strip it from albumin’s own transport site, and free or loosely bound copper is a classical catalyst for oxidative damage to proteins, acting mainly on methionine, cysteine, tryptophan, histidine and tyrosine side chains.

BPC-157’s published sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Reading that off, it contains none of the five residues copper oxidation chemistry is best known to target. That is a genuine, checkable point in favour of this specific pairing being less chemically fragile than a copper peptide mixed with a methionine- or cysteine-bearing molecule would be. It is not the same as a stability study. Nobody has actually tested whether copper transfers, whether it accelerates degradation through some other pathway, or whether either peptide is stable in the other’s presence over the weeks a reconstituted vial sits in a refrigerator, and no such study was located for this entry.

Potential benefits and research applications

Skin and connective-tissue repair, a combination of two separate reputations

What is being investigated: whether combining a copper-binding tripeptide with a gastric-derived healing peptide supports skin and soft-tissue repair better than either alone. How the effect might occur: GHK-Cu is proposed to signal through TGF-beta and related wound-healing pathways in skin, while BPC-157 is proposed to support angiogenesis and tissue repair through mechanisms that remain contested in its own literature. Evidence: each compound has its own separate body of animal and limited human evidence for repair-related outcomes, reviewed in their own site entries. Strength: has been reported anecdotally for the combination specifically; each component individually ranges from preliminary to contested evidence on its own. Limitation: no study, animal or human, has tested GHK-Cu and BPC-157 administered together for any outcome, so whatever benefit either shows alone cannot be assumed to add up, let alone combine favorably, when given as a pair.

Reduced injection-site irritation, a claim that circulates but has not been tested

What is being investigated: whether adding BPC-157 to a GHK-Cu injection reduces the site irritation some people report with GHK-Cu alone. How the effect might occur: proposed through BPC-157’s general anti-inflammatory reputation, not a specific mechanism. Evidence: this claim was located in enthusiast and vendor writing, framed as a hypothesis. Strength: has been reported anecdotally; has not been established. Limitation: no study measuring injection-site reaction with and without BPC-157 present was found, so this is reported here only as something that circulates, not as a demonstrated effect.

What is known about the combination

No study, animal or human, that tested GHK-Cu and BPC-157 administered together was located for this entry. Two 2026 scoping and narrative reviews in The American Journal of Sports Medicine cover both peptides, among others, for musculoskeletal and sports-medicine use, but each reviews the two compounds on their own literatures; neither describes a study in which the two were given together, and neither uses the word combination or blend for this pair.

No registered trial of this combination exists on ClinicalTrials.gov. A claim that circulates in product-facing material, that adding BPC-157 reduces the injection-site pain some people report with GHK-Cu, was located in enthusiast and vendor writing reviewed for this entry, framed there as a hypothesis based on BPC-157’s general anti-inflammatory reputation rather than as a tested finding. No study measuring injection-site reaction with and without BPC-157 present was found, so that claim is reported here only as something that circulates, not as something established.

What the component evidence actually says

Both peptides have their own entries on this site, and both are worth reading before this blend makes sense. In brief:

  • BPC-157 has no identified receptor after roughly 230 published papers, about 77 percent of which come from one laboratory in Zagreb. Its three published human reports come from one clinic in Florida, thirty-one patients in total, with no control group.
  • GHK-Cu is the compound on this site where circulating dose and documented practice are furthest apart: topical figures used in product range from 0.05 to 3 percent, a sixty-fold spread, and its flagship TGF-beta mechanism is contested in the primary literature rather than settled.

Putting two compounds in a vial does not combine their evidence bases. It combines their separate unknowns and adds a question about their interaction that nobody has studied.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objectiveRoute reportedAmount reportedFrequency reportedReported durationEvidence or source category
Skin and gut, combined doseSubcutaneous10 units, about 0.10 mL, from a vial reconstituted per the 50mg/10mg splitOnce daily4–6 weeks on, 2–4 offCommunity/vendor reported
GHK-Cu delivered per doseSubcutaneousAbout 1.66 mgOnce daily4–6 weeksCommunity/vendor reported
BPC-157 delivered per doseSubcutaneousAbout 333 mcgOnce daily4–6 weeksCommunity/vendor reported

No dose-ranging study of this pair, or any study of the two given together at any dose, exists. Checked against each component’s own circulating convention, this split does not obviously overshoot or undershoot either one: the GHK-Cu figure lands inside the 1–2 mg daily range described on GHK-Cu’s own entry, and the BPC-157 figure lands inside the 250–500 mcg range described on the Wolverine entry. At roughly 16% copper by mass, the 1.66 mg GHK-Cu dose works out to about 266 mcg of elemental copper injected daily, against an oral adult recommended intake of 900 mcg, and injection bypasses the intestine’s normal copper-absorption regulation; no study has measured serum copper or ceruloplasmin in anyone using this or any other GHK-Cu-containing blend.

What is not known

Whether copper redistributes between the peptide and its surroundings in a mixed solution, and whether either component degrades faster because of it. Whether the 5:1 ratio has any pharmacological basis, or is a convenient round number carried over from the three- and four-peptide blends that share the same GHK-Cu figure. Whether combining the two changes injection-site reactions in either direction; the claim that it helps is reported here as circulating, not demonstrated. Whether the combination does anything a single component would not, in any measured outcome, in any species. Everything already unknown about each component alone, which on the BPC-157 side includes carcinogenicity and human pharmacokinetics, and on the GHK-Cu side includes the direction of its central signalling mechanism.

Regulatory status

Neither component is an approved drug. BPC-157 was recommended for the 503A compounding list by the FDA Pharmacy Compounding Advisory Committee in July 2026, against FDA staff’s own recommendation, and the agency has not acted on that recommendation. GHK-Cu’s regulatory attention runs through a different channel: it has drawn scrutiny from the Cosmetic Ingredient Review panel over the concentrations used in topical products, not from an FDA drug-compounding action, and no FDA warning letter or advisory-committee vote specific to GHK-Cu as an injectable was located for this entry.

Frequently asked questions

What is GHK-Cu / BPC-157?

It is a vendor blend of two peptides in one vial, usually a 5:1 ratio of GHK-Cu to BPC-157. Neither component is an approved drug, and no study has tested the two given together.

How does it work?

GHK-Cu is proposed to signal through TGF-beta and related pathways in skin; BPC-157 is proposed to support tissue repair through mechanisms still contested in its own literature. Combining them in one vial does not combine or test their mechanisms together.

What dosage has been studied?

None. No dose-ranging study of this pair, or any study of the two given together at any dose, exists.

What dosage commonly circulates online?

Vials are commonly described as 50 mg GHK-Cu to 10 mg BPC-157 in 3 mL, with a 10-unit draw delivering roughly 1.66 mg GHK-Cu and about 333 mcg BPC-157 daily. Checked against each component’s own circulating convention, this split does not obviously overshoot or undershoot either one.

Has it been studied in humans?

Not as a combination. Each component has its own separate, limited literature, reviewed in their own entries on this site, but no registered trial of this pairing exists on ClinicalTrials.gov.

Does BPC-157 reduce GHK-Cu injection-site irritation?

That claim circulates in vendor and enthusiast material but has not been tested. No study measuring injection-site reaction with and without BPC-157 present was found.

What side effects have been reported?

None specific to this combination have been studied. Injected GHK-Cu delivers roughly 266 mcg of elemental copper daily by this entry’s math, bypassing the intestine’s normal copper-absorption regulation, and no study has measured serum copper or ceruloplasmin in anyone using this or any similar blend.

Is it approved?

No. Neither component is an approved drug, and the combination has no regulatory status of its own.

What remains unknown?

Whether copper redistributes between the two peptides in solution and accelerates degradation; whether the 5:1 ratio has any pharmacological basis; whether the combination does anything a single component would not; and everything already unknown about each component separately.

Bottom line

GHK-Cu / BPC-157 combines two peptides with their own separate, limited evidence bases into one vial, without a single study testing whether that combination does anything the components would not do alone. BPC-157’s sequence happens to lack the amino acids copper oxidation chemistry usually targets, a genuine point in this pairing’s favor, but no stability or compatibility study has confirmed it. Neither peptide is an approved drug, and the injected copper dose bypasses the body’s normal absorption regulation with no monitoring data to say what that means.

Reported amounts and the evidence behind them: GHK-Cu dosage: topical percentages and injected amounts reported online.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
Skin and gut, combined doseSubcutaneous10 units, about 0.10 mLOnce daily4 to 6 weeks on, 2 to 4 off
GHK-Cu delivered per doseSubcutaneousAbout 1.66 mgOnce daily4 to 6 weeks
BPC-157 delivered per doseSubcutaneousAbout 333 mcgOnce daily4 to 6 weeks

A 10-unit draw from a vial reconstituted this way delivers roughly 1.66 mg of GHK-Cu and about 333 micrograms of BPC-157. Checked against each component's own circulating convention, the GHK-Cu figure lands inside the 1 to 2 mg daily range described on GHK-Cu's own entry, and the BPC-157 figure lands inside the 250 to 500 microgram range described on the Wolverine entry. Unlike several blends on this site, this particular split does not obviously overshoot or undershoot either component's own convention, which is worth stating plainly rather than treating every blend the same way.

On the copper: 1.66 mg of GHK-Cu, at roughly 16 percent copper by mass, works out to about 266 micrograms of elemental copper injected daily, against an oral adult recommended intake of 900 micrograms. Injection bypasses the intestine, which is where the body ordinarily regulates copper absorption, and no study has measured serum copper or ceruloplasmin in anyone using this or any other GHK-Cu-containing blend.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Share thisFacebookXEmail